Vitrakvi for Adult and Pediatric Solid Tumors

News
Article

Vitrakvi Product Image

Vitrakvi (larotrectinib, Bayer and Loo Oncology Inc)

Indications: treatment of adult and pediatric patients with solid tumors that:

  • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,

  • are metastatic or where surgical resection is likely to result in severe morbidity, and

  • have no satisfactory alternative treatments or that have progressed following treatment.

Dosage:

  • Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared: 100 mg orally twice daily

  • Pediatric Patients with Body Surface Area of Less Than 1.0 Meter-Squared: 100 mg/m2 orally twice daily

Contraindications: None

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.